AF
INZY

Amalgamated Financial’s Inozyme Pharma INZY Stock Holding History

Amalgamated Financial’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$7K Buy
+1,732
New +$10.2K ﹤0.01% 2938

Other funds holding INZY

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Amalgamated Financial's INZY Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Inozyme Pharma (INZY) in Q1 2022: 1,732 shares worth $7K. The stake represents ﹤0.01% of the portfolio and ranks #2938 among its holdings.

50 funds tracked by Wall St. Rank hold INZY as of Q1 2022.

  • Amalgamated Financial held 1,732 shares of Inozyme Pharma worth $7K as of Q1 2022.
  • Inozyme Pharma was a new Amalgamated Financial position in Q1 2022.
  • Inozyme Pharma made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2938 holding.
  • 50 funds tracked by Wall St. Rank held Inozyme Pharma as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.